Multiple myeloma

The PBS subsidises lenalidomide and pomalidomide for patients with multiple myeloma.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with lenalidomide and pomalidomide under section 100 of the National Health Act 1953, for a patient with multiple myeloma.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines restrictions for prescribing lenalidomide and pomalidomide.

Section 100 arrangements

Lenalidomide and pomalidomide

These items are only PBS subsidised for day admitted patients, non-admitted patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

These items aren't PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

Lenalidomide

Applying for initial treatment as monotherapy for newly diagnosed disease

Patients receiving lenalidomide under this PBS listing must be registered in the i-access risk management program.

Apply for initial authority approval to prescribe PBS subsidised lenalidomide as monotherapy for the treatment of newly diagnosed multiple myeloma in writing and either:

All applications must include the completed:

Initial treatment as dual therapy for newly diagnosed disease

Patients receiving lenalidomide under this PBS listing must be registered in the i-access risk management program.

Apply for initial authority approval to prescribe PBS subsidised lenalidomide as dual therapy for the treatment of newly diagnosed multiple myeloma in writing and either:

All applications must include the completed:

Applying for initial treatment as triple therapy for newly diagnosed disease

Patients receiving lenalidomide under this PBS listing must be registered in the i-access risk management program.

Apply for initial authority approval to prescribe PBS subsidised lenalidomide as triple therapy for the treatment of newly diagnosed multiple myeloma in writing and either:

All applications must include the completed:

Applying for initial treatment - progressive disease

Patients receiving lenalidomide under this PBS listing must be registered in the i-access risk management program.

Apply for initial authority approval to prescribe PBS subsidised lenalidomide for the treatment of progressive multiple myeloma in writing and either:

All applications must include the completed:

Applying for continuing treatment

Authority applications to prescribe continuing PBS subsidised lenalidomide to treat multiple myeloma, where applicable, can be made either:

Pomalidomide

Applying for initial treatment

Patients receiving pomalidomide under this PBS listing must be registered in the i-access risk management program.

Apply for initial authority approval to prescribe PBS subsidised pomalidomide for the treatment of multiple myeloma in writing and either:

All applications must include the completed:

Applying for continuing treatment

Authority applications to prescriber continuing PBS subsidised pomalidomide for patients with multiple myeloma, call the PBS Complex Drugs Programs enquiry line.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 5 June 2020